AstraZeneca has recently announced organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a new phase in its strategic development.

Included in the changes will be the arrival at AstraZeneca of the world-renowned oncology scientist, José Baselga, as well as the creation of:

• Therapy area-focused Research and Development units that are responsible for discovery through to late-stage development - one for BioPharmaceuticals (Cardiovascular, Renal & Metabolism (CVRM) and Respiratory) and one for Oncology - with dynamic resource allocation across the Company’s pipeline.
• Mirrored commercial units - one for BioPharmaceuticals and one for Oncology. The creation of the BioPharmaceuticals commercial unit aligns product strategy and commercial delivery across CVRM and Respiratory.

The Research and Development units and the commercial units will each be represented on the Senior Executive Team of AstraZeneca and report to Chief Executive Officer (CEO), Pascal Soriot.

The Research and Development unit for BioPharmaceuticals will be led by Mene Pangalos, who was previously responsible for the Company’s Innovative Medicines and Early Development Biotech Unit.

The Research and Development unit for Oncology will be led by Dr. Baselga, a foremost Oncology leader with vast experience in the development of innovative cancer therapies.